Prescription Drug Advertising
Governs advertising for prescription drugs: the requirement for a true statement of information in brief summary relating to side effects, contraindications and effectiveness, fair balance between benefit and risk, and the categories of presentation FDA treats as false or misleading.
What this does not cover
stated in the document's own scope- It covers prescription drug advertisements; over-the-counter drug advertising is overseen by the Federal Trade Commission.
- Brochures, mailing pieces, detailing pieces and similar materials are labeling, not advertising (202.1(l)(2)).
- Reminder advertisements that make no representation about the drug are exempt from the brief summary requirement, subject to conditions.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Part 202 is FDA’s regulation on prescription drug advertising. It implements section 502(n) of the FD&C Act, which requires advertisements for prescription drugs to include a true statement of information in brief summary relating to side effects, contraindications and effectiveness. It sets out when that brief summary is required and how it may be provided, the standard of fair balance between benefit and risk information, the presentations FDA considers false, lacking in fair balance or otherwise misleading, and, since 2024, the standard for the major statement in television and radio advertisements directed to consumers.
Scope & applicability
Prescription-drug advertisements, including direct-to-consumer broadcast and print. Promotional labelling — the material distributed by or on behalf of the sponsor that is not an advertisement — is reached through the labelling provisions instead, which is why promotional review has to consider both.
Legal basis & how it acquires force
A regulation in Title 21 of the Code of Federal Regulations issued under sections 502(n) and 701 of the FD&C Act. An advertisement that does not comply makes the drug misbranded. The most recent amendment, published on 21 November 2023 and in effect from 20 May 2024, set the standard that the major statement in consumer-directed television and radio advertisements be presented in a clear, conspicuous and neutral manner.
Document structure
| Part | Covers |
|---|---|
| 202.1(e)(1)–(2) — When a brief summary is required | All prescription drug advertisements, except the exempt categories such as reminder advertisements |
| 202.1(e)(1) — Broadcast advertisements | The major statement of the major side effects and contraindications in audio, or audio and text, and adequate provision for disseminating the approved labeling |
| 202.1(e)(1)(ii) — Clear, conspicuous and neutral | Consumer-friendly language, understandable audio, dual-modality text in television ads, and no distracting presentation |
| 202.1(e)(5)–(7) — Fair balance and misleading advertisements | Presentations that are false, lacking in fair balance or otherwise misleading |
| 202.1(j) — Prior approval | Circumstances in which an advertisement may not be disseminated without FDA’s prior approval |
| 202.1(l) — Advertisements and labeling | Media that are advertisements, and materials such as brochures and detailing pieces that are labeling |
Key requirements
- §202.1(e) — the true statement requirement: brief summary of side effects, contraindications and effectiveness
- Fair balance in the presentation of benefit and risk information
- §202.1(e)(6) — presentations FDA considers false, lacking in fair balance, or otherwise misleading
- The adequate-provision alternative for broadcast advertisements under §202.1(e)(1)
Implementation tips
- Review promotional material against the authorised indication and the approved labelling, not against the brand strategy — a claim beyond the authorisation is an enforcement matter, not a marketing dispute
- Record what the reviewer checked against: the approved labelling version is the control, and it moves
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Part 202 governs advertisements; promotional labeling is governed through the labeling provisions of the FD&C Act and 21 CFR Part 201, and section 202.1(l) helps draw the line. Promotional materials for marketed drugs are submitted to FDA at first use under the postmarketing reporting rules for applications. The Federal Trade Commission oversees advertising for over-the-counter drugs.
21 CFR Part 202: frequently asked questions
Quick answers to common questions about 21 CFR Part 202.
What is the “major statement” in a broadcast advertisement?
The presentation of the drug’s major side effects and contraindications in the audio, or audio and visual, parts of a broadcast advertisement. Consumer-directed television and radio advertisements must present it in a clear, conspicuous and neutral manner.
What does “clear, conspicuous and neutral” require?
Consumer-friendly language; audio at least as understandable as the rest of the advertisement; in television, the statement presented in both audio and text at the same time, with text that is easy to read and on screen for as long as the audio; and no audio or visual elements likely to interfere with comprehension.
When did the clear, conspicuous and neutral standard take effect?
The final rule was published on 21 November 2023 and took effect on 20 May 2024.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.